Bristol-Myers Squibb Gets European Union Approval for MS Drug Zeposia
May 27 2020 - 7:47AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. on Wednesday said the European
Commission approved Zeposia for the treatment of adults with
relapsing remitting multiple sclerosis with active disease.
The New York biopharmaceutical company said Zeposia, an oral
once-daily medication, becomes the only EC-approved
sphingosine-1-phosphate receptor modulator for such patients with
active disease.
Bristol-Myers, which in March received U.S. Food and Drug
Administration for Zeposia for adults with relapsing forms of
multiple sclerosis, is also developing the drug for additional
immune-inflammatory indications, including ulcerative colitis and
Crohn's disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 27, 2020 07:32 ET (11:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
